What happened
Prof Rob Galloway, an emergency doctor, launched Rare People - The Research Charity to fund clinical trials for rare genetic diseases. His daughter's diagnosis with DeSanto Shinawi syndrome, an ultra-rare condition affecting approximately 200 people globally, inspired the initiative. The charity supports trials of repurposed medicines identified by artificial intelligence, a strategy Galloway recognised after US scientists used AI to find an epilepsy drug showing "signs of possible benefit" in cells from a child with the syndrome. This approach uses AI computing power to analyse global experimental data.
Why it matters
AI-driven drug repurposing offers a new pathway to accelerate treatments for ultra-rare genetic diseases, which often lack existing therapies. This mechanism, applying AI to analyse vast experimental data for new applications of existing drugs, could significantly reduce the timeline and cost associated with de novo drug development. For biotech founders and clinical trial teams, this model presents a scalable approach potentially applicable to thousands of conditions. Monitor the progress of these AI-driven repurposing trials as a blueprint for addressing unmet medical needs in niche disease areas.
Subscribe for Weekly Updates
Stay ahead with our weekly AI and tech briefings, delivered every Tuesday.
